Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Glenmark Pharmaceuticals Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

23 Jul 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - Glenmark Pharmaceuticals Ltd (GLENMARK-IN)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

27 Jul 2016 Thomson Reuters Stock Report 11 $25.00

Glenmark Pharmaceuticals Ltd. (GLENMARK) - Financial Analysis Review

Glenmark Pharmaceuticals Ltd. (GLENMARK) - Financial Analysis Review Summary Glenmark Pharmaceuticals Ltd. (Glenmark Pharmace...

21 Jul 2016 GlobalData 59 $300.00

Spark Capital: Glenmark Pharmaceuticals – FY16 annual report analysis

Glenmark Pharmaceuticals – FY16 annual report analysis Business highlights: 13 ANDAs were filed during the year includi...

21 Jul 2016 Spark Capital Advisors(India) Private Limited 7 $58.00

Glenmark Pharmaceuticals Ltd: Downgraded to Average

15 Jul 2016 Sadif Analytics Prime 3 $10.00

Wright Investors Service Comprehensive Report for Glenmark Pharmaceuticals Ltd

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

12 Jul 2016 Wright Reports 60 $75.00

Glenmark Pharmaceuticals Ltd. (GLENMARK) - Financial Analysis Review

Glenmark Pharmaceuticals Ltd. (GLENMARK) - Financial Analysis Review Summary Glenmark Pharmaceuticals Ltd. (Glenmark Pharmace...

17 Jun 2016 GlobalData 58 $300.00

Spark Capital: 4QFY16 outlook review of Glenmark Pharmaceuticals (Rating: SELL, TP: Rs. 799)

4QFY16 outlook review of Glenmark Pharmaceuticals (Rating: SELL, TP: Rs. 799) How does our one year outlook change? We ...

17 May 2016 Spark Capital Advisors(India) Private Limited 6 $46.00

MOSL: GLENMARK PHARMA 4QFY16 (Neutral)-Results in line-US business ramp-up is the key

GLENMARK PHARMA 4QFY16: Results in line; US business ramp-up is the key (GNP IN, Mkt Cap USD3.5b, CMP INR869, TP INR900, 4% ...

16 May 2016 Motilal Oswal Securities Ltd. 12 $115.00

Glenmark Pharmaceuticals (GNP IN)_Q4FY16 Result Update

Glenmark Pharmaceuticals (GNP IN) sales as well as adjusted PAT were above estimates, led by strong sales growth as well as i...

16 May 2016 IndiaNivesh Securities Pvt Ltd 7 $69.00